Your browser is no longer supported. Please, upgrade your browser.
Settings
SNDX Syndax Pharmaceuticals, Inc. daily Stock Chart
SNDX [NASD]
Syndax Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.76 Insider Own0.20% Shs Outstand34.33M Perf Week-24.31%
Market Cap725.51M Forward P/E- EPS next Y-1.79 Insider Trans15.63% Shs Float33.16M Perf Month34.10%
Income-57.00M PEG- EPS next Q-0.48 Inst Own65.20% Short Float5.32% Perf Quarter52.63%
Sales1.50M P/S483.67 EPS this Y36.90% Inst Trans15.97% Short Ratio2.13 Perf Half Y122.55%
Book/sh1.56 P/B10.06 EPS next Y14.50% ROA-68.60% Target Price20.00 Perf Year107.81%
Cash/sh2.19 P/C7.16 EPS next 5Y- ROE-123.60% 52W Range5.35 - 21.97 Perf YTD78.70%
Dividend- P/FCF- EPS past 5Y-3.90% ROI-182.10% 52W High-28.58% Beta1.93
Dividend %- Quick Ratio5.50 Sales past 5Y- Gross Margin- 52W Low193.27% ATR2.11
Employees35 Current Ratio5.50 Sales Q/Q0.00% Oper. Margin- RSI (14)45.96 Volatility12.70% 12.07%
OptionableYes Debt/Eq0.37 EPS Q/Q16.10% Profit Margin- Rel Volume1.30 Prev Close15.69
ShortableYes LT Debt/Eq0.37 EarningsMay 07 AMC Payout- Avg Volume828.31K Price15.69
Recom1.70 SMA20-15.82% SMA5016.73% SMA20061.85% Volume0 Change0.00%
May-22-20Upgrade Citigroup Neutral → Buy $26 → $23
May-22-20Downgrade H.C. Wainwright Buy → Neutral $25 → $15
May-18-20Downgrade Citigroup Buy → Neutral
May-11-20Reiterated H.C. Wainwright Buy $19 → $25
Mar-04-20Initiated Barclays Overweight $15
Jan-13-20Reiterated H.C. Wainwright Buy $15 → $17
Mar-08-19Reiterated H.C. Wainwright Buy $22 → $16
Jan-04-19Initiated Robert W. Baird Outperform
Jan-05-18Initiated B. Riley FBR, Inc. Buy $40
Mar-16-17Initiated FBR & Co. Outperform $27
Mar-02-17Initiated Instinet Buy $27
Oct-07-16Initiated Guggenheim Buy
Mar-28-16Initiated Morgan Stanley Overweight $22
Mar-28-16Initiated JMP Securities Mkt Outperform $28
Mar-28-16Initiated Citigroup Buy $24
May-25-20 03:17PM  Does Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Have A Particularly Volatile Share Price? Simply Wall St.
May-22-20 04:17PM  Fiery Biotech Stock Crashes On Late-Stage Failure In Breast Cancer Investor's Business Daily -21.95%
May-21-20 04:35PM  ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2- Breast Cancer PR Newswire
May-12-20 04:05PM  Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
May-09-20 10:31PM  Syndax Pharmaceuticals (SNDX) Q1 2020 Earnings Call Transcript Motley Fool
May-08-20 03:00PM  Edited Transcript of SNDX earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents
May-07-20 08:10PM  Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:05PM  Syndax Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Business Update PR Newswire
Apr-30-20 07:51AM  Syndax Announces Pricing of Public Offering of Common Stock PR Newswire
07:00AM  Syndax to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 7, 2020 PR Newswire
Apr-29-20 04:35PM  Syndax Announces Proposed Public Offering of Common Stock PR Newswire
08:40AM  The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda Benzinga
Apr-28-20 04:09PM  Why This Bullishly Ranked Biotech Stock Just Broke Out To A Record High Investor's Business Daily +69.42%
03:09PM  Why Kura Oncology Is Skyrocketing Today Motley Fool
12:52PM  Why Syndax Is Skyrocketing 55% Today Motley Fool
07:36AM  The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update Benzinga
Apr-27-20 04:05PM  Syndax Pharmaceuticals Announces Preclinical Profile and Initial Phase 1 Data Demonstrating Clinical Activity of Menin Inhibitor SNDX-5613 in Adults with Relapsed/Refractory Acute Leukemias PR Newswire
12:31PM  Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
Apr-14-20 07:00AM  Syndax Pharmaceuticals Announces Three Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting PR Newswire +12.60%
Apr-03-20 06:04PM  Edited Transcript of SNDX earnings conference call or presentation 3-Mar-20 9:30pm GMT Thomson Reuters StreetEvents -8.21%
Mar-05-20 06:54AM  Will Syndax Pharmaceuticals Continue to Surge Higher? Zacks +6.38%
Mar-03-20 05:55PM  Syndax Pharmaceuticals (SNDX) Reports Q4 Loss Zacks -5.41%
04:05PM  Syndax Pharmaceuticals Reports Fourth Quarter 2019 Financial Results and Provides Clinical and Business Update PR Newswire
Feb-18-20 07:00AM  Syndax Announces Participation at Two Upcoming Investor Conferences PR Newswire +5.22%
Feb-07-20 11:05AM  The CEO & Director of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), Briggs Morrison, Just Bought 40% More Shares Simply Wall St.
Feb-04-20 07:01AM  Syndax Pharmaceuticals, Inc. (SNDX) Shares March Higher, Can It Continue? Zacks +12.34%
Jan-31-20 07:00AM  Syndax Announces $35.0 Million Offering of Common Stock and Enters Term Sheet for Loan with Hercules Capital for up to $30 Million PR Newswire +40.84%
Jan-30-20 02:11PM  Science Magazine Publishes Results from Preclinical Study on the Activity of Menin-MLL Inhibition for the Treatment of NPM1 Acute Myeloid Leukemia PR Newswire
Jan-24-20 10:20AM  Should Syndax Pharmaceuticals (NASDAQ:SNDX) Be Disappointed With Their 40% Profit? Simply Wall St. -7.85%
Jan-10-20 04:05PM  Syndax Pharmaceuticals Highlights 2020 Clinical and Corporate Outlook PR Newswire
Dec-17-19 04:39PM  Should You Avoid Syndax Pharmaceuticals, Inc. (SNDX)? Insider Monkey
Dec-10-19 08:08AM  Are Insiders Buying Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock? Simply Wall St.
07:00AM  Syndax Pharmaceuticals Announces Plans to Commence Phase 2 Expansion Cohort of SNDX-6352 for the Treatment of Chronic Graft Versus Host Disease PR Newswire
Dec-09-19 04:05PM  Syndax Announces Preclinical Results Supporting Development of its Portfolio of Menin Inhibitors In Mixed Lineage Leukemias PR Newswire
Nov-17-19 07:14AM  Edited Transcript of SNDX earnings conference call or presentation 7-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-11-19 09:30AM  Do Hedge Funds Love Syndax Pharmaceuticals, Inc. (SNDX)? Insider Monkey
Nov-07-19 05:55PM  Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:05PM  Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update PR Newswire
Nov-06-19 07:00AM  Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias PR Newswire
Oct-31-19 07:00AM  Syndax to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7, 2019 PR Newswire
Oct-28-19 10:32AM  Will Syndax Pharmaceuticals (SNDX) Report Negative Q3 Earnings? What You Should Know Zacks
Oct-23-19 12:44PM  Can We See Significant Institutional Ownership On The Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Share Register? Simply Wall St.
Sep-17-19 11:42AM  Is Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) CEO Being Overpaid? Simply Wall St.
Sep-11-19 10:04AM  Implied Volatility Surging for Syndax (SNDX) Stock Options Zacks
Aug-29-19 11:41AM  Edited Transcript of SNDX earnings conference call or presentation 7-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-28-19 07:00AM  Syndax Announces Participation at Four Upcoming Investor Conferences PR Newswire
Aug-12-19 08:46AM  3 Hot Healthcare Stocks That Wont Break the Bank TipRanks
Aug-09-19 09:37AM  Looking At Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) From All Angles Simply Wall St.
Aug-07-19 06:25PM  Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:05PM  Syndax Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Clinical and Business Update PR Newswire
Aug-05-19 07:00AM  Syndax to Participate in the BTIG Biotechnology Conference PR Newswire
Jul-31-19 07:00AM  Syndax to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 7, 2019 PR Newswire
Jul-30-19 10:38AM  Will Syndax Pharmaceuticals (SNDX) Report Negative Q2 Earnings? What You Should Know Zacks
06:11AM  7 Stocks to Buy With Over 20% Upside From Current Levels InvestorPlace
Jul-12-19 05:41AM  A Trio of Small Biotech Companies Garnering Attention TheStreet.com
Jul-10-19 07:00AM  Syndax Pharmaceuticals Announces FDA Clearance of IND Application for Targeted Menin Inhibitor SNDX-5613 for Relapsed/Refractory Acute Leukemias PR Newswire
Jul-04-19 07:26AM  Introducing Syndax Pharmaceuticals (NASDAQ:SNDX), A Stock That Climbed 29% In The Last Year Simply Wall St.
Jun-13-19 07:00AM  Syndax to Present at the JMP Securities Life Sciences Conference PR Newswire
Jun-08-19 08:28PM  Edited Transcript of SNDX earnings conference call or presentation 6-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-30-19 05:33AM  5 Stellar Stocks For Under $10 TipRanks
May-28-19 11:18AM  Sirnaomics Appoints Allan L. Shaw as Chief Financial Officer PR Newswire
May-16-19 10:45AM  Have Insiders Been Buying Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares This Year? Simply Wall St.
May-14-19 07:00AM  Syndax to Present at the UBS Global Healthcare Conference PR Newswire
May-06-19 06:05PM  Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:53PM  Syndax: 1Q Earnings Snapshot Associated Press
04:05PM  Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update PR Newswire
Apr-29-19 07:00AM  Syndax to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 6, 2019 PR Newswire
Apr-01-19 10:33AM  Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meeting PR Newswire -6.67%
Mar-27-19 07:00AM  Syndax Announces $26.2 Million Offering of Common Stock and Warrants PR Newswire +16.09%
Mar-13-19 03:45AM  Edited Transcript of SNDX earnings conference call or presentation 7-Mar-19 9:30pm GMT Thomson Reuters StreetEvents -5.42%
Mar-12-19 01:35PM  What Do Analysts Think About Syndax Pharmaceuticals, Inc.s (NASDAQ:SNDX) Earnings Trend? Simply Wall St. +5.73%
Mar-07-19 04:05PM  Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update PR Newswire
Mar-06-19 07:00AM  Syndax to Present at the Cowen 39th Annual Health Care Conference PR Newswire -8.92%
Feb-28-19 07:00AM  Syndax to Announce Fourth Quarter and Year-end 2018 Financial Results and Host Conference Call and Webcast on March 7, 2019 PR Newswire
Feb-27-19 04:47PM  Syndax Announces Clinical Data from its Entinostat Immuno-oncology Program Selected for Two Oral Presentations at the American Association for Cancer Research Annual Meeting 2019 PR Newswire
Feb-25-19 10:30AM  Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release Zacks
Feb-12-19 07:55AM  New Research: Key Drivers of Growth for Cronos Group, Spectrum Brands, Black Hills, Entercom Communications, CSS Industries, and Syndax Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-07-19 07:00AM  Syndax Highlights 2019 Clinical and Corporate Outlook PR Newswire +14.17%
Jan-04-19 12:23PM  Can We See Significant Institutional Ownership On The Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Share Register? Simply Wall St. +15.96%
Dec-04-18 12:17AM  Edited Transcript of SNDX earnings conference call or presentation 5-Nov-18 9:30pm GMT Thomson Reuters StreetEvents -9.36%
Dec-03-18 10:00AM  Syndax Pharmaceuticals Announces Presentation of Preclinical Data from Menin-MLL Program at the 60th American Society of Hematology Annual Meeting PR Newswire +6.86%
Nov-12-18 08:50AM  Investor Expectations to Drive Momentum within CommScope Holding, AMC Networks, Henry Schein, Lindblad Expeditions, Apple Hospitality REIT, and Syndax Pharmaceuticals Discovering Underlying Factors of Influence GlobeNewswire
Nov-05-18 06:30PM  Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue Estimates Zacks -5.08%
04:05PM  Syndax Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Clinical and Business Update PR Newswire
Nov-01-18 04:05PM  Syndax Pharmaceuticals Announces Presentations at the 60th American Society of Hematology Annual Meeting PR Newswire
Oct-29-18 07:00AM  Syndax to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 5, 2018 PR Newswire -7.98%
Oct-26-18 08:17AM  The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default Benzinga -17.05%
Oct-25-18 04:05PM  Syndax to Host Conference Call to Provide Update on the Phase 3 Breast Cancer Trial (E2112) and to Announce its Registration Trial of Entinostat with Keytruda in PD-(L)1 Refractory Non-Small Cell Lung Cancer PR Newswire
Oct-18-18 08:35AM  Report: Exploring Fundamental Drivers Behind Syndax Pharmaceuticals, Arconic, Del Taco Restaurants, Aerohive Networks, KalVista Pharmaceuticals, and Adtalem Global Education New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Sep-26-18 07:00AM  Syndax to Present at the 2018 Cantor Global Healthcare Conference PR Newswire
Sep-25-18 04:05PM  Syndax Announces Changes to its Board of Directors PR Newswire
08:51AM  Do Options Traders Know Something About Syndax (SNDX) Stock We Don't? Zacks
08:30AM  The Daily Biotech Pulse: Syndax Lung Cancer Trial Disappoints, Gemphire To Trim Workforce, Opiant's Offering Benzinga
Sep-24-18 04:05PM  Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer PR Newswire +6.79%
Sep-12-18 03:54PM  Are Syndax Pharmaceuticals Incs (NASDAQ:SNDX) Interest Costs Too High? Simply Wall St. -9.79%
Sep-11-18 12:27PM  Edited Transcript of SNDX earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Sep-05-18 05:00PM  Syndax to Present at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer PR Newswire
Aug-28-18 07:00AM  Syndax Announces Participation at Three Upcoming Investor Conferences PR Newswire
Aug-27-18 08:15AM  New Research: Key Drivers of Growth for REGENXBIO, Syndax Pharmaceuticals, Rowan Companies, CTS, Basic Energy Services, and Impinj Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Aug-07-18 06:20PM  Syndax Pharmaceuticals (SNDX) Reports Q2 Loss Zacks
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates are entinostat that is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 in Phase I/II clinical trial inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. It also develops entinostat with Keytruda (pembrolizumab) in a Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and melanoma or microsatellite stable colorectal carcinoma; and with Tecentriq (atezolizumab) in Phase Ib/II clinical trials to treat patients with HR+ and HER2- metastatic breast cancer. In addition, the company develops SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 that is in Phase I/II clinical trial in patients with chronic graft versus host disease; and as a monotherapy and in combination with Imfinzi (durvalumab), which is completed Phase Ib dose trials for the treatment of solid tumors. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH; Genentech, Inc.; and Merck KGaA and Pfizer. It also has collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Morrison BriggsChief Executive OfficerFeb 04Buy8.0012,500100,00043,900Feb 05 04:07 PM